Headed to San Francisco? Here’s how you can customize your experience at #JPM24 with Endpoints News

Bioregnum Opinion Column by John Carroll

A lot of biotechs turned to survival mode back in the summer of 2022, and it’s clear from our recent surveys and panel discussions that the caution will spill right into next year.

Click here to view original post